Cannell & Spears LLC Has $78,000 Stock Position in Biodesix, Inc. $BDSX

Cannell & Spears LLC lowered its stake in shares of Biodesix, Inc. (NASDAQ:BDSX) by 95.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,279 shares of the company’s stock after selling 195,326 shares during the quarter. Cannell & Spears LLC’s holdings in Biodesix were worth $78,000 as of its most recent SEC filing.

Separately, XTX Topco Ltd raised its stake in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after acquiring an additional 102,494 shares during the last quarter. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Insider Transactions at Biodesix

In related news, CEO Scott Hutton sold 3,559 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the transaction, the chief executive officer owned 45,413 shares in the company, valued at approximately $457,763.04. The trade was a 7.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jack W. Schuler bought 20,000 shares of the stock in a transaction on Monday, January 26th. The stock was purchased at an average cost of $11.80 per share, with a total value of $236,000.00. Following the purchase, the director directly owned 1,563,210 shares of the company’s stock, valued at approximately $18,445,878. This represents a 1.30% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 10,999 shares valued at $116,095. Corporate insiders own 30.10% of the company’s stock.

Analyst Ratings Changes

BDSX has been the topic of a number of research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 target price on shares of Biodesix in a research report on Tuesday, February 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Finally, William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a research report on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.50.

Biodesix Stock Performance

BDSX stock opened at $17.29 on Tuesday. Biodesix, Inc. has a twelve month low of $3.44 and a twelve month high of $20.21. The company has a quick ratio of 1.86, a current ratio of 1.87 and a debt-to-equity ratio of 41.11. The company has a market cap of $170.48 million, a P/E ratio of -3.56 and a beta of 0.58. The business’s fifty day moving average is $11.93 and its 200-day moving average is $9.06.

Biodesix (NASDAQ:BDSX) last released its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.56. Biodesix had a negative return on equity of 1,760.83% and a negative net margin of 39.85%.The firm had revenue of $28.76 million for the quarter, compared to analyst estimates of $26.25 million. Equities research analysts forecast that Biodesix, Inc. will post -0.35 EPS for the current year.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.